A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study.

@article{Schuster2015API,
  title={A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study.},
  author={James J. Schuster and Rose K. Lai and Lawrence Recht and David A Reardon and Nina A. Paleologos and Morris D. Groves and Maciej M. Mrugala and Randy Jensen and Joachim M. Baehring and Andrew M Sloan and Gary E. Archer and Darell D Bigner and Scott Cruickshank and Jennifer A Green and Tibor Keler and Thomas A. Davis and Amy Heimberger and John H. Sampson},
  journal={Neuro-oncology},
  year={2015},
  volume={17 6},
  pages={854-61}
}
BACKGROUND The epidermal growth factor receptor variant III deletion mutation, EGFRvIII, is expressed in ∼30% of primary glioblastoma and linked to poor long-term survival. Rindopepimut consists of the unique EGFRvIII peptide sequence conjugated to keyhole limpet hemocyanin. In previous phase II trials (ACTIVATE/ACT II), rindopepimut was well tolerated with robust EGFRvIII-specific immune responses and promising progression-free and overall survival. This multicenter, single-arm phase II… CONTINUE READING
78 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 78 extracted citations

Similar Papers

Loading similar papers…